Fusidic acid in other infections.
Fusidic acid, both systemic and topical, has been used for a wide variety of less common infections. Efficacy for oral fusidic acid has been demonstrated in the treatment of Clostridium difficile colitis and in staphylococcal infections in patients with cystic fibrosis. Topical fusidic acid gel is also effective in bacterial conjunctivitis and other minor external eye infections, and may be effective in reducing bacterial flora in the conjunctival sac prior to eye surgery. Studies suggest a potential role for fusidic acid in neurosurgical prophylaxis, as adjunctive therapy in bacterial endophthalmitis and Legionella pneumonia, and in leprosy. Topical fusidic acid has no effect in the treatment of chlamydial conjunctivitis or the prevention of staphylococcal infections in patients on continuous ambulatory peritoneal dialysis.
Golledge
C
C
Department of Microbiology and Infectious Diseases, Queen Elizabeth 11 Medical Centre, Nedlands, WA, Australia. clay.golledge@health.wa.gov.au
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016360:Clostridioides difficile; D003231:Conjunctivitis / Q000188:drug therapy; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy; D009877:Endophthalmitis / Q000188:drug therapy; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy; D005672:Fusidic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017053:Infection Control; D007239:Infections / Q000188:drug therapy*; D015440:Leprosy, Lepromatous / Q000188:drug therapy; D009493:Neurosurgery; D009883:Ophthalmic Solutions; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D011014:Pneumonia / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000209:etiology
D000900:Anti-Bacterial Agents; D009883:Ophthalmic Solutions; D005672:Fusidic Acid